BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27003102)

  • 1. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Haery L; Mussakhan S; Waxman DJ; Gilmore TD
    Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
    Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
    Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.
    Garbati MR; Thompson RC; Haery L; Gilmore TD
    Cancer Lett; 2011 Mar; 302(1):76-83. PubMed ID: 21232847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
    Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
    Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.
    Garbati MR; Alço G; Gilmore TD
    Cancer Lett; 2010 May; 291(2):237-45. PubMed ID: 19948376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
    Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
    Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
    Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
    Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction.
    Baluchamy S; Sankar N; Navaraj A; Moran E; Thimmapaya B
    Oncogene; 2007 Feb; 26(5):781-7. PubMed ID: 16862175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
    Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription.
    Faiola F; Liu X; Lo S; Pan S; Zhang K; Lymar E; Farina A; Martinez E
    Mol Cell Biol; 2005 Dec; 25(23):10220-34. PubMed ID: 16287840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
    Bakhshi TJ; Way T; Muncy B; Georgel PT
    Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 18. Cooperation of SRC-1 and p300 with NF-kappaB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells.
    Sahar S; Reddy MA; Wong C; Meng L; Wang M; Natarajan R
    Arterioscler Thromb Vasc Biol; 2007 Jul; 27(7):1528-34. PubMed ID: 17495236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
    Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.